Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Chemoradiation for anal cancer

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Anal cancer is one of the clearest success stories in oncology. It used to be treated by removing the anus and rectum and creating a permanent colostomy. Chemoradiation replaced that for most people, with equal or better survival and the anatomy left intact.

Two things about it are commonly misunderstood: a genetic test that should happen before the chemotherapy starts, and how long you are supposed to wait before judging whether it worked.

Related pages: Anal cancer

The bottom line

What we know
  • Concurrent chemoradiation is the standard treatment for most anal cancers.
  • Tumours continue to shrink for months after radiation ends.
  • Surgery is reserved for persistent or recurrent disease.
  • DPYD gene variants cause severe, sometimes fatal, toxicity from fluorouracil.
What is still open
  • The best chemotherapy partner for radiation in older or less fit patients, where trials continue.
  • Whether immunotherapy will have a role in earlier-stage disease.

The story, step by step

  1. 1. What it is ()
  2. 2. DPYD ()
  3. 3. Waiting ()
  4. 4. Salvage ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 4

Radiation and chemotherapy together

Review of many studies

What happens

The regimen, in outline.

What the research shows

  • Radiation is given daily on weekdays, usually over about 5 to 6 weeks, to the anus and the pelvic and groin lymph nodes.
  • Modern delivery uses intensity-modulated radiotherapy, IMRT, which shapes the dose around the target and has substantially reduced skin, bowel and blood-count toxicity compared with older techniques.
  • Chemotherapy runs at the same time, most often 5-fluorouracil with mitomycin. Capecitabine, a tablet form of the same family, is used in place of infused 5-FU in some protocols.
  • The chemotherapy is given at doses that make the radiation work better rather than at doses intended to treat the cancer on their own.
  • Mitomycin suppresses blood counts, so blood tests are frequent and a low count can delay a cycle.
  • People with HIV are treated with the same approach, with attention to counts and interactions; outcomes with modern antiretroviral therapy are broadly comparable.

Why it matters

The anatomy-preserving part is the point: for most people this treatment ends with a functioning anus, which is what the alternative operation removes.

What's still uncertain

  • The optimal chemotherapy partner for people who cannot tolerate mitomycin, which is an active question.

Read more

Next: DPYD

Part 2 of 4

The test that should come first

Review of many studies

What happens

A safety step many patients have never heard of.

What the research shows

  • The DPD enzyme breaks down fluorouracil and capecitabine. Around 6 percent of people carry a DPYD gene variant that reduces that activity, and a small number have almost none.
  • In those people, standard doses can cause severe mucositis, diarrhoea, blood count collapse and, rarely, death.
  • Testing is standard practice across Europe, the United Kingdom, Australia and much of Canada. The United States moved more slowly: the FDA added a boxed warning to capecitabine's label in late 2025 recommending DPYD testing before treatment, and updated the fluorouracil label in February 2026 to recommend the same.
  • Historically, testing was done in well under 1 percent of United States patients starting these drugs, so being asked about it is still not guaranteed.
  • Where a variant is found, the dose is reduced according to an established algorithm, or another approach is used. It does not mean treatment is off the table.
  • Asking whether DPYD testing has been done before starting 5-FU or capecitabine is a reasonable question, and the answer is increasingly yes.

Why it matters

This is the single most actionable safety point in anal cancer treatment, and the practice around it changed very recently.

What's still uncertain

  • How quickly universal testing will become routine in the United States, which is in flux.

Read more

Next: Waiting

Part 3 of 4

Why response is judged at six months

Review of many studies

What happens

The most counterintuitive part of this treatment.

What the research shows

  • Anal tumours continue to shrink for weeks and months after radiation finishes. A tumour still palpable at the end of treatment is expected, not a failure.
  • Response is assessed at around 26 weeks, roughly six months, from the start of treatment. Many tumours that look incomplete at 11 weeks have resolved entirely by then.
  • This matters because biopsying or operating too early leads to unnecessary permanent colostomies. The ACT II trial established the later assessment point for exactly this reason.
  • Monitoring in the interval is by examination, which should show steady regression rather than growth.
  • Growth, or new symptoms, at any point is assessed promptly. Slow residual shrinkage is not.
  • The waiting is hard. Knowing that the schedule is deliberate, and that it exists to avoid removing an anus that did not need removing, helps some people.

Why it matters

If someone suggests surgery because a lump is still there a few weeks after treatment, the six-month assessment point is worth raising.

What's still uncertain

  • The ideal assessment timing in individual cases, which is a judgement balanced against the risk of missing persistent disease.

Read more

Next: Salvage

Part 4 of 4

Surgery, if it is needed

Review of many studies

What happens

What happens when chemoradiation does not clear it.

What the research shows

  • Where disease persists at the six-month assessment, or recurs later, the operation is an abdominoperineal resection: removal of the anus, rectum and surrounding tissue, with a permanent colostomy.
  • It is major surgery with a long recovery and a significant wound, and it is also potentially curative, which is why it is offered.
  • A permanent stoma is a large change and is manageable. Stoma nurses exist precisely for this and should be met before surgery rather than after.
  • A smaller number of people need a temporary stoma during chemoradiation itself, usually because the tumour is obstructing or causing a fistula.
  • Metastatic disease, which is uncommon at diagnosis, is treated with chemotherapy and, increasingly, immunotherapy, which is a separate pathway from the one described here.
  • Clinical trials are worth asking about, particularly for recurrent or metastatic disease, where options are developing.

Why it matters

Most people never need this, which is the achievement of the chemoradiation approach. It is listed because knowing the backstop exists is better than discovering it under pressure.

What's still uncertain

  • The role of immunotherapy in persistent local disease, which is being studied.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.